Abbreviated Biparametric MRI for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new MRI scan method for men with newly diagnosed prostate cancer. The scan combines detailed imaging and water movement analysis to detect cancer. The goal is to see if this method is as effective as the standard MRI but simpler and cheaper.
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications.
Is Abbreviated Biparametric MRI safe for humans?
How is the Abbreviated Biparametric MRI treatment different from other prostate cancer treatments?
The Abbreviated Biparametric MRI (RSI + T2WI) is a quicker and simpler imaging method compared to the traditional multiparametric MRI, taking about 15 minutes instead of 40. It uses fewer scan sequences, making it a more efficient option for detecting and managing prostate cancer, especially in men who have not yet had a biopsy.678910
What data supports the effectiveness of the treatment Abbreviated Biparametric MRI (RSI + T2WI) for prostate cancer?
Research shows that multiparametric MRI, which includes T2-weighted imaging, is effective in diagnosing and managing prostate cancer. A study comparing biparametric MRI (which includes T2-weighted imaging) to multiparametric MRI found it useful for diagnosing prostate cancer, suggesting that the abbreviated version may still be effective.611121314
Who Is on the Research Team?
Aradhana Venkatesan
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for treatment-naive patients with clinically significant prostate cancer (Gleason score > 3+4, cancer core length > 4mm) needing an MRI before treatment or biopsy. Excluded are those with pacemakers, conditions preventing MR imaging at 3T, under age 18, unable to use an endorectal coil, prior androgen therapy or prostate treatments, over 400 pounds weight, unable to consent or recent biopsy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Biopsy
Participants undergo T2 weighted imaging (T2WI) and restriction spectrum imaging (RSI) for prostate cancer detection, followed by MRI/US fusion guided biopsy
Follow-up
Participants are monitored for safety and effectiveness after imaging and biopsy procedures
What Are the Treatments Tested in This Trial?
Interventions
- Abbreviated Biparametric MRI (RSI + T2WI)
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor